Skip to main content

Erdanib 4 mg & 5 mg (Erdafitinib)

This reference hub prioritizes regulatory agencies, official labeling, peer-reviewed research and documented pharmaceutical-development information.

Regulatory Sources

U.S. Food and Drug Administration — BALVERSA

The FDA prescribing information provides the current U.S. indication, diagnostic requirement, dosage, administration, warnings, adverse reactions and clinical pharmacology.

DailyMed — BALVERSA

DailyMed provides the current structured U.S. labeling record, including product strengths and packager information.

European Medicines Agency — Balversa

The EMA provides EU authorization information, indication, safety information and product details. The current EPAR identifies the EU marketing authorization issued in August 2024 and was updated in June 2026.

Clinical evidence

The THOR phase 3 study was published in the New England Journal of Medicine in 2023 and provides randomized evidence comparing erdafitinib with chemotherapy in selected FGFR-altered advanced urothelial carcinoma.

Pharmaceutical-development sources

Astex documents the discovery of erdafitinib through its collaboration with Janssen and describes the 2008 worldwide license and collaboration arrangement.

Erdanib-specific documentation

The manufacturer, regulatory authorization, marketing authorization holder and official product documentation for Erdanib are:

[Information requires verification]